Last updated: 2026-09-09 04:51:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vericel Corporation (VCEL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $39.08, with a market capitalization of $2.06B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $28.95 to $49.32. This page covers its latest market performance, valuation, price trends and company information.
$2.06B | |
$39.69 | |
$68.94 | |
$1.69 | |
$40.19 | |
326.70K | |
563.29K | |
-- | |
$49.32 | |
$28.95 | |
-- | |
-- |
Vericel Corporation (VCEL) last closed at $40.19 as of 2026-09-08 23:31:00, unchanged from the previous close of $40.19.
During the latest regular trading session, VCEL traded between $1.69 and $68.94, with a volume of 326.70K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Vericel Corporation (VCEL) moved from $41.18 to $39.08, representing a decline of 5.11% ($2.10).
The stock traded between $38.21 and $42.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 474.56 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 49.7%
VCEL is currently trading at $39.08, placing it 49.7% of the way from its 52-week low of $28.95 to its 52-week high of $49.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 398 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vericel Corporation (VCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.